OTC · Medical - Diagnostics & Research

CelLBxHealth plc (ANPCY) Stock

$0.07 +0.00% OTC: ANPCY Healthcare

Headquartered in Guildford, United Kingdom, and established in 1994, CelLBxHealth plc (formerly known as ANGLE plc until October 2025) is a medical diagnostics company dedicated to advancing cancer detection. The firm's reach extends globally, with operations in the UK, Europe, and North America.

Valuation

MetricValue
Price$0.07
Market Cap$21.98M
P/E Ratio-0.15
P/B Ratio1.22
P/S Ratio11.12
EPS (TTM)$-0.48
52-Week High$2.39
52-Week Low$0.07
Dividend Yield0.00%

Financials & Margins

MetricValue
ROE-77.78%
ROA-56.00%
ROCE-68.18%
Gross Margin62.16%
Operating Margin-527.46%
Net Margin-497.03%
Debt/Equity0.23
Current Ratio5.04

Annual Financials (USD)

Metric20202021202220232024
Revenue$1.0M$1.0M$1.0M$2.0M$3.0M
Operating Profit$-14.0M$-17.0M$-24.0M$-22.0M$-15.0M
Net Profit$-12.0M$-15.0M$-22.0M$-20.0M$-14.0M
EPS$-0.65$-0.67$-0.88$-0.77$-0.48
Op Margin-1802.0%-1701.4%-2325.4%-995.4%-527.5%

Balance Sheet (USD)

Metric20202021202220232024
Total Assets$39.0M$47.0M$50.0M$31.0M$25.0M
Total Liabilities$5.0M$7.0M$10.0M$8.0M$7.0M
Cash$12.0M$32.0M$32.0M$16.0M$10.0M
Borrowings$1.0M$2.0M$5.0M$5.0M$4.0M

Latest News

Amazon Advertising Up 26% In Q2, Profits Soar To $62.6B MediaPost · Jul 31, 2026 History Says That Nvidia Is an Unbelievable Bargain Right Now Motley Fool · Jul 31, 2026 UNITE HERE Local 11 Releases Letter Urging Greene County Ohio Board of Commissioners and Captain Tony Buschur to Consider Aramark’s Problematic Track Record in Prison Food Service and Award Contract to Alternate Provider Business Wire · Jul 31, 2026 Dow Jones Futures: Apple, Amazon Diverge Late; What To Do After AI Stocks Surge Investor's Business Daily · Jul 31, 2026 Anthropic's models gained unauthorized 'real-world' access during testing AFP · Jul 31, 2026

Cash Flow (USD)

Metric20202021202220232024
Operating Cash Flow$-8.0M$-14.0M$-16.0M$-14.0M$-13.0M
Investing Cash Flow$-2.0M$13.0M$-4.0M$-1.0M$0
Financing Cash Flow$0$0$0$0$0
Net Cash Flow$8.0M$20.0M$0$-16.0M$-6.0M
Free Cash Flow$-8.0M$-16.0M$-18.0M$-15.0M$-14.0M

Valuation & Return Ratios

MetricValue
PEG Ratio—
EV / EBITDA-1.97
FCF Yield-63.71%
Quick Ratio4.55
Interest Coverage—
Return 1Y—
Return 3Y—
Return 5Y—

Peer Comparison

TickerPriceChangeP/EMarket CapDiv Yield
ECGSEco-Growth Strategies Inc. $0.04 -23.21% -2.54 $2.45M 0.00%
EGRXEagle Pharmaceuticals, Inc. $0.37 -15.91% 0.13 $4.87M 0.00%
FPCGAvem Health Partners, Inc. $1025.00 +0.00% 1.35 $10.07M 0.00%
JMPHFLeveljump Healthcare Corp. $0.04 +0.00% -1.59 $8.12M 0.00%
LVCLFAlgorae Pharmaceuticals Limited $0.01 +0.00% 26.00 $16.36M 0.00%

About CelLBxHealth plc

Headquartered in Guildford, United Kingdom, and established in 1994, CelLBxHealth plc (formerly known as ANGLE plc until October 2025) is a medical diagnostics company dedicated to advancing cancer detection. The firm's reach extends globally, with operations in the UK, Europe, and North America. CelLBxHealth's product portfolio features innovative medical devices such as the Parsortix PC1 system, specifically engineered to isolate and collect intact circulating tumor cells (CTCs) from the blood of metastatic breast cancer patients for subsequent user-validated analysis. They also offer the Parsortix PR1 system for general CTC capture. Further enhancing their diagnostic capabilities are the Portrait+ CTC Staining kit, a ready-to-use laboratory tool providing high analytical sensitivity and specificity for the identification, characterization, and enumeration of epithelial and mesenchymal CTCs, alongside the CellKeep Slide for efficient CTC harvesting. In addition to its product line, the company provides comprehensive laboratory services, including CTC enrichment and liquid biopsy analysis. Their specialized assays encompass Portrait Flex, an immunofluorescence test for identifying epithelial, mesenchymal, and epithelial-to-mesenchymal transition (EMT) cells, as well as assessing DNA damage response. They also offer Portrait PD-L1 for evaluating CTCs and develop bespoke CTC assays. Strategic alliances are a key component of their development strategy, including a partnership with BioView Ltd to create a human epidermal growth factor receptor 2 (HER2) assay kit for breast cancer, and an agreement with NuProbe USA, Inc. to leverage a pan-cancer next-generation sequencing (NGS) panel.

CelLBxHealth plc is headquartered in GB.

CelLBxHealth plc (ANPCY) stock trades at $0.07 with a market capitalization of $21.98M. The stock is valued at a price-to-earnings (P/E) ratio of -0.15, price-to-book of 1.22, price-to-sales of 11.12. Over the past 52 weeks the stock has ranged between $0.07 and $2.39, and currently trades 97.1% below its 52-week high.

On profitability, CelLBxHealth plc generates a return on equity (ROE) of -77.78%, return on capital employed of -68.18%, an operating margin of -527.46%, a net profit margin of -497.03%.

Official website: cellbxhealth.com

Related Healthcare Stocks

LLY Drug Manufacturers - General $1185.71 -0.52% JNJ Drug Manufacturers - General $259.24 +0.88% ABBV Drug Manufacturers - General $246.04 +0.89% UNH Medical - Healthcare Plans $407.08 +0.77% MRK Drug Manufacturers - General $128.57 +0.16% NVS Drug Manufacturers - General $158.83 -0.64% NVO Biotechnology $51.58 +1.22% TMO Medical - Diagnostics & Research $594.00 +2.41% AMGN Drug Manufacturers - General $387.64 -1.39% ABT Medical - Devices $108.03 +0.70% GILD Drug Manufacturers - General $132.73 -1.18% PFE Drug Manufacturers - General $26.74 +2.06%

Popular Stocks

Apple (AAPL)Microsoft (MSFT)NVIDIA (NVDA)Alphabet (GOOGL)Amazon (AMZN)Meta (META)Tesla (TSLA)Broadcom (AVGO)JPMorgan (JPM)Visa (V)

Screens featuring this stock

High ROE Healthcare StocksLow P/E Healthcare StocksHigh Net Margin Healthcare StocksDividend Healthcare StocksLow Debt Healthcare StocksAll stock screens
Run Stock Screener Investing Guides